Flexion Therapeutics Inc (FLXN) Given Consensus Rating of “Hold” by Analysts

Shares of Flexion Therapeutics Inc (NASDAQ:FLXN) have received an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $39.00.

FLXN has been the topic of a number of recent analyst reports. BidaskClub downgraded Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 8th. Zacks Investment Research raised Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Friday, August 10th. ValuEngine cut Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 21st. Finally, Wells Fargo & Co set a $39.00 price objective on Flexion Therapeutics and gave the stock a “buy” rating in a report on Monday, October 22nd.

NASDAQ FLXN traded up $0.15 during trading on Monday, reaching $16.46. 585,844 shares of the company’s stock were exchanged, compared to its average volume of 627,394. The company has a market cap of $617.44 million, a PE ratio of -3.96 and a beta of 1.17. The company has a quick ratio of 8.74, a current ratio of 8.88 and a debt-to-equity ratio of 1.02. Flexion Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $29.10.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($1.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.09. The firm had revenue of $6.99 million for the quarter, compared to the consensus estimate of $5.93 million. Flexion Therapeutics had a negative return on equity of 88.21% and a negative net margin of 1,346.87%. As a group, research analysts anticipate that Flexion Therapeutics will post -4.64 EPS for the current fiscal year.

In related news, insider Michael D. Clayman purchased 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 9th. The stock was acquired at an average cost of $17.10 per share, for a total transaction of $85,500.00. Following the completion of the purchase, the insider now owns 83,295 shares in the company, valued at approximately $1,424,344.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO David Arkowitz purchased 4,000 shares of the business’s stock in a transaction that occurred on Friday, November 9th. The stock was bought at an average price of $16.56 per share, with a total value of $66,240.00. Following the completion of the purchase, the chief financial officer now owns 48,250 shares of the company’s stock, valued at approximately $799,020. The disclosure for this purchase can be found here. Insiders own 14.59% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System boosted its stake in shares of Flexion Therapeutics by 22.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,896 shares of the specialty pharmaceutical company’s stock valued at $411,000 after buying an additional 2,960 shares during the period. Redmile Group LLC boosted its stake in shares of Flexion Therapeutics by 33.5% in the second quarter. Redmile Group LLC now owns 13,260 shares of the specialty pharmaceutical company’s stock valued at $343,000 after buying an additional 3,330 shares during the period. Alps Advisors Inc. boosted its stake in shares of Flexion Therapeutics by 8.5% in the second quarter. Alps Advisors Inc. now owns 54,622 shares of the specialty pharmaceutical company’s stock valued at $1,412,000 after buying an additional 4,272 shares during the period. Dupont Capital Management Corp boosted its stake in shares of Flexion Therapeutics by 15.9% in the third quarter. Dupont Capital Management Corp now owns 31,688 shares of the specialty pharmaceutical company’s stock valued at $593,000 after buying an additional 4,354 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Flexion Therapeutics by 3.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 179,658 shares of the specialty pharmaceutical company’s stock valued at $4,645,000 after buying an additional 5,257 shares during the period.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Further Reading: Why do company’s buyback their stock?

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit